Literature DB >> 30529129

The antibiotic resistance-free mammalian expression plasmid vector pPAL for development of third generation vaccines.

Pedro J Alcolea1, Ana Alonso2, Vicente Larraga3.   

Abstract

DNA vaccines require a vector to replicate genes and express encoding antigens. Antibiotic resistance genes are often used as selection markers, which must not be released to the environment upon final product commercialization. For this reason, generation of antibiotic resistance-free vectors is imperative. The pPAL vector contains the cytomegalovirus enhancer and promoter for expression in mammalian cells and the E. coli fabI chromosomal gene as a selectable marker. The fabI gene encodes the enoyl-ACP reductase (FabI). The bacteriostatic compound triclosan is an inhibitor of this enzyme. Therefore, the selection of positive clones depends on the enzyme:inhibitor molar ratio. According to western blot analysis, the pPAL vector is functional for expression of the Leishmania infantum (Kinetoplastid: Trypanosomatidae) gene encoding for the protein kinase C receptor analog (LACK/p36) in the HEK293T human cell line transfected with pPAL-LACK. The fabI gene sequence contains a 210 bp CpG island, suggesting a potential role as an adjuvant of the antibiotic resistance-free pPAL vector. In fact, Th1 response induction levels against canine leishmaniasis only using pPAL-LACK was shown to be as strong as in previous strategies using a recombinant vaccinia virus in combination with standard mammalian expression plasmid vectors. In summary, the pPAL plasmid contains the essential elements for manipulation and expression of any cloned DNA sequence in prokaryotic and mammalian cells using an E. coli endogenous gene as a selectable marker, which also provides a long CpG island. This element enhances Th1 immune response against L. infantum infection in dogs using the gene encoding for the LACK antigen. Therefore, this antibiotic resistance-free plasmid is a vaccine vector actively participating in protection against canine leishmaniasis and may be potentially tested as a vaccine vector with other antigens against different pathogens.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CpG islands; Enoyl-ACP reductase; LACK/p36; Leishmaniasis; Plasmid; Selection marker; Th1 response; Third generation vaccine; Triclosan

Mesh:

Substances:

Year:  2018        PMID: 30529129     DOI: 10.1016/j.plasmid.2018.12.002

Source DB:  PubMed          Journal:  Plasmid        ISSN: 0147-619X            Impact factor:   3.466


  3 in total

Review 1.  Alicante-Winter Immunology Symposium in Health (A-Wish) and the Boulle-SEI awards: A collaboration between the Spanish Society for immunology, the University of Alicante and the Jean Boulle Group to honor the Balmis Expedition.

Authors:  Jordi Ochando; Carmen Camara; Leighton Durham; Jose Miguel Sempere; Marcos Lopez-Hoyos
Journal:  Curr Res Immunol       Date:  2022-06-18

2.  IL12 p35 and p40 subunit genes administered as pPAL plasmid constructs do not improve protection of pPAL-LACK vaccine against canine leishmaniasis.

Authors:  Pedro J Alcolea; Ana Alonso; Adriana Esteban; Paz Peris; Alberto Cortés; Juan A Castillo; Vicente Larraga
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

3.  Leishmania infantum UBC1 in Metacyclic Promastigotes from Phlebotomus perniciosus, a Vaccine Candidate for Zoonotic Visceral Leishmaniasis.

Authors:  Jaime Larraga; Pedro J Alcolea; Ana M Alonso; Luis T C Martins; Inmaculada Moreno; Mercedes Domínguez; Vicente Larraga
Journal:  Vaccines (Basel)       Date:  2022-02-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.